The U.S. Food and Drug Administration (FDA) has approved the first prescription medication specifically for treating o ...

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

Disappointing trial results for Novo Nordisk A/S’s experimental obesity shot capped a volatile year for investors in drug ...

The U.S. Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

Novo Nordisk's Wegovy and Eli Lilly's Zepbound are so far the leaders in this market. According to Reuters, the following is ...

Eli Lilly (NYSE: LLY) soared more than 60% from the start of the year through its peak this summer, thanks to the company's ...

Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the ...

Specialty pharmacies and online companies that have been selling off-brand copies of two blockbuster drugs for obesity and ...

Zepbound is Eli Lilly’s weight loss drug. Now, it is also a drug to treat obstructive sleep apnea (OSA).The U.S. Food and ...

By week 72, patients given Zepbound lost 20.2% of their body weight on average ... Meanwhile, Lilly’s Phase III SUMMIT trial (NCT04847557) found that tirzepatide reduced the risk of heart failure ...

Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep ...